Scientists Find the Gut-Barrier Breakdown Behind Gout Attacks

Gout does not start in the joint. Long before a swollen, throbbing big toe sends someone to the emergency room, the trouble may already be brewing in the gut, where roughly a third of the body's uric acid is supposed to be filtered out. A new mouse study from Fujian University of Traditional Chinese Medicine, published in iScience, traces a specific chain of events, from a shift in gut bacteria to a breakdown in the intestinal wall to two separate cell-signaling pathways, that appears to shut that excretion route down at each stage of gout's progression. The findings are still confined to a mouse model, but they offer the clearest mechanistic map yet of how the gut turns from a uric acid exit ramp into part of the problem.

Key takeaways

• In mice, both early hyperuricemia and full gout flares involved a weakened gut barrier, marked by lower levels of the proteins Occludin, Claudin-1, and ZO-1 that normally seal the intestinal lining together.
• Two separate signaling pathways, ErbB3/PI3K/AKT and ADRB2/cAMP/PKA/CREB, turned on in step with disease severity, with the second appearing only once a full gout attack was underway.
• Bacteria taken from the sick mice's guts, applied to human intestinal cells in a dish, reproduced the same barrier damage, suggesting the microbes themselves are an active driver, not just a bystander.
• This is animal and cell-culture work; none of it has yet been confirmed in people with gout.

Gut Microbiota Shift Drives Uric Acid Excretion Failure

Researchers found that mice with hyperuricemia (chronically high blood uric acid) and mice with acute gouty arthritis (a full flare triggered by uric acid crystals in the joint) both showed a disrupted gut microbiome alongside a leaky intestinal barrier and, ultimately, impaired excretion of uric acid through the gut. The team identified 11 bacterial genera that were altered in the same direction in both the milder hyperuricemia stage and the more severe gout-flare stage, a signature they argue tracks the disease from onset through to attack. Alongside the microbial shift, the mice showed lower levels of three intestinal barrier proteins, Occludin, Claudin-1, and Zonula occludens-1 (known as ZO-1, a protein that helps hold neighboring gut cells together), plus higher blood levels of two markers of gut leakiness, DAO and D-LA. The gut's uric acid export pump, a transporter called ABCG2, was also dialed down, while a transporter that pulls uric acid back into the body, GLUT9, was dialed up, a combination that works against the gut's normal job of clearing roughly 30 to 40 percent of the body's uric acid through the intestinal route.

Why Gout Patients Should Care About the Gut Connection

Gout affects a large and growing share of the population, with prevalence reaching as high as 6.8 percent in some regions and a trend toward younger patients, and it is notoriously prone to flares that recur even with treatment. Most gout management focuses on the kidneys and on limiting purine-rich foods, but this study adds weight to a growing body of work suggesting the gut itself is a second, and possibly manipulable, excretion route. If a damaged gut lining and an altered microbiome are actively suppressing that route, as this mouse data suggests, then people managing hyperuricemia, gout, or related conditions like metabolic syndrome may eventually have a second lever to work with, alongside kidney-focused urate-lowering therapy, once this is tested directly in humans. It is also relevant to anyone already dealing with a gut-barrier or microbiome-linked condition, since the same barrier proteins studied here (Occludin, Claudin-1, ZO-1) are the ones commonly discussed in leaky-gut research tied to IBS and IBD.

Two Mouse Models Traced Gout From Onset to Flare

The researchers built two sequential mouse models using Kunming mice: a hyperuricemia model, produced by 21 days of a high-fat, high-sugar diet plus daily doses of hypoxanthine and potassium oxonate (compounds that raise uric acid production), and an acute gouty arthritis model, built by taking the same hyperuricemic mice and injecting monosodium urate crystals directly into a knee joint to trigger a flare. Each group, control, hyperuricemia, and gout-flare, contained six mice. To test whether the gut bacteria themselves were doing the damage rather than just changing alongside it, the team extracted intact bacterial communities from each group of mice and applied them directly to human colon cell cultures (NCM460 cells) in the lab. Bacteria from both the hyperuricemia and gout-flare mice caused the same pattern of membrane damage, mitochondrial swelling, and barrier-protein loss in these dish-grown cells that the researchers saw in the live mice, which is the strongest piece of evidence in the paper that the microbial shift is a cause of the damage rather than merely a downstream effect of it. RNA sequencing of gut tissue then pinpointed which internal signaling circuits were driving the damage: the ErbB3/PI3K/AKT pathway was active in both disease stages, while the ADRB2/cAMP/PKA/CREB pathway, centered on the stress hormone receptor ADRB2 and the signaling molecule cAMP, switched on specifically once the acute gout flare began, and follow-up protein tests in the mice confirmed both patterns.

What the Findings Mean, and Do Not Yet Mean, for People

For someone managing gout or watching their uric acid levels, the practical takeaway from this study is limited but pointed: it strengthens the case that gut health, not just kidney function and diet, is mechanistically tied to how well the body clears uric acid, and it identifies specific bacteria and barrier proteins that could eventually become blood or stool biomarkers worth discussing with a doctor as testing matures. Nothing here, however, establishes that a particular probiotic, supplement, or diet change can fix this pathway in a person; the study did not test any intervention aimed at restoring the microbiome or the gut barrier, and mouse gut biology does not always translate directly to human physiology. Anyone with gout or recurrent hyperuricemia should treat this as a piece of the mechanistic puzzle, not a treatment recommendation, and continue following their physician's guidance on urate-lowering therapy and diet.

Limitations: A Mouse Study Awaiting Human Confirmation

The authors are explicit about the gaps. The intestinal analysis focused only on the jejunum (part of the small intestine), leaving the colon, where most gut bacteria actually live, unexamined for barrier protein changes. The cell-culture experiments showed that whole bacterial communities from sick mice caused damage, but did not isolate which specific species or bacterial byproducts were responsible, and no gene-silencing or pathway-blocking experiments were run to directly confirm that the ErbB3/PI3K/AKT or ADRB2/cAMP/PKA/CREB pathways are the actual cause of the barrier breakdown rather than a downstream consequence of it. Most importantly, every finding comes from Kunming mice and a human cell line grown in a dish; none of it has been validated in gout patients, and the paper does not claim otherwise.

What Comes Next for Gut-Targeted Gout Research

The research team has laid out a fairly specific follow-up plan: extending the analysis to the colon to build a complete picture of gut barrier changes, running metabolomic profiling on the bacterial cultures to identify which specific microbial byproducts, such as short-chain fatty acids or purine breakdown products, are driving cell damage, and using gene-silencing experiments to directly test whether blocking the two signaling pathways prevents the barrier breakdown. The authors also state plainly that the next necessary step is validating the 11 shared bacterial genera and the two pathways in clinical samples from actual hyperuricemia and gout patients, which has not yet happened.

Common Questions

Is this gut-microbiome mechanism proven in humans with gout? No. Every result in this study comes from mouse models and a human cell line grown in a lab dish; the authors state that clinical validation in gout patients is a needed next step.

Which gut barrier proteins were affected? Occludin, Claudin-1, and ZO-1, three proteins that help seal the junctions between intestinal cells, were all reduced in both the hyperuricemia and gout-flare mice, with a larger drop during the acute flare.

What are the two signaling pathways involved, and are they different? ErbB3/PI3K/AKT was active in both hyperuricemia and gout-flare mice, suggesting it plays a role throughout disease progression, while ADRB2/cAMP/PKA/CREB turned on only during the acute flare, suggesting it is specific to that more severe stage.

Does this mean a probiotic or supplement could help gout? Not based on this study. No probiotic, supplement, or microbiome-targeting treatment was tested here; the paper only maps the mechanism by which gut bacteria appear to worsen uric acid excretion.

References

1. Meiling Wang, Ruifang Yang, Honglin An, et al. (2026). Gut microbiota and uric acid excretion signaling in pathogenesis of hyperuricemia and acute gouty arthritis. iScience. https://doi.org/10.1016/j.isci.2026.117072
2. Atsushi Hosomi, Takeo Nakanishi, Takuya Fujita, Ikumi Tamai (2012). Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2. PLoS ONE. https://doi.org/10.1371/journal.pone.0030456
3. Mats Dehlin, Lennart Jacobsson, Edward Roddy (2020). Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-020-0441-1
4. Qiulan Lv, Jun Zhou, Changyao Wang, et al. (2023). A dynamics association study of gut barrier and microbiota in hyperuricemia. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2023.1287468